Tenecteplase

Pharmacologic Category

Thrombolytic Agent

Dosing: Adult

Acute ischemic stroke (off-label use): Note: May be preferred for IV thrombolysis in eligible patients with acute ischemic stroke who are also eligible to undergo mechanical thrombectomy (AHA/ASA [Powers 2019]).

IV: 0.25 mg/kg (maximum total dose: 25 mg) once; administer within 4.5 hours of symptom onset (AHA/ASA [Powers 2019]; Campbell 2018; Campbell 2020).

Pulmonary embolism, acute (hemodynamically unstable/massive) (off-label use): IV: Administer dose as a single bolus over 5 to 10 seconds (Kline 2007; Melzer 2004):

<60 kg: 30 mg

≥60 to <70 kg: 35 mg

≥70 to <80 kg: 40 mg

≥80 to <90 kg: 45 mg

≥90 kg: 50 mg

Pulmonary embolism, acute (hemodynamically stable/submassive) (off-label use): Note: Not recommended for most patients with acute pulmonary embolism without hypotension; use only in select patients showing signs of clinical deterioration despite maintaining a systolic BP >90 mm Hg where benefits outweigh risks (Kearon 2012; Kearon 2016).

IV: Administer dose as a single bolus over 5 to 10 seconds (Kline 2007; Kline 2014; Melzer 2004; Meyer 2014):

<60 kg: 30 mg

≥60 to <70 kg: 35 mg

≥70 to <80 kg: 40 mg

≥80 to <90 kg: 45 mg

≥90 kg: 50 mg

Pulmonary embolism associated with cardiac arrest (off-label use): IV: Administer as a single bolus over 5 seconds (Böttiger 2008; Bozeman 2006):

<60 kg: 30 mg

≥60 to <70 kg: 35 mg

≥70 to <80 kg: 40 mg

≥80 to <90 kg: 45 mg

≥90 kg: 50 mg

ST-elevation myocardial infarction: IV: The recommended total dose should not exceed 50 mg and is based on weight. Administer as a single bolus over 5 seconds:

<60 kg: 30 mg

≥60 to <70 kg: 35 mg

≥70 to <80 kg: 40 mg

≥80 to <90 kg: 45 mg

≥90 kg: 50 mg

Note: Thrombolytic should be administered within 30 minutes of hospital arrival. Generally, there is only a small trend for benefit of therapy after a delay of 12 to 24 hours from symptom onset, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation; however, primary PCI is preferred in these patients. Administer concurrent aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, or fondaparinux) with tenecteplase (O’Gara 2013).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing. Although dosage adjustments are not recommended, the elderly have a higher incidence of morbidity and mortality with the use of tenecteplase.

Dosing: Renal Impairment: Adult

No dosage adjustment necessary.

Hemodialysis: Dialyzable: Unknown, but unlikely (NCS/SCCM [Frontera 2016])

Dosing: Hepatic Impairment: Adult

Mild to moderate impairment: No dosage adjustment provided in manufacturer's labeling.

Severe impairment: No dosage adjustment provided in manufacturer's labeling; weigh the risk of bleeding against the benefits with tenecteplase especially in those with a coagulopathy.

Use: Labeled Indications

ST-elevation myocardial infarction: Management of ST-elevation myocardial infarction (STEMI) for the lysis of thrombi in the coronary vasculature to restore perfusion and reduce mortality.

Recommended criteria for treatment of STEMI (ACC/AHA [O’Gara 2013]): Ischemic symptoms within 12 hours of treatment or evidence of ongoing ischemia 12 to 24 hours after symptom onset with a large area of myocardium at risk or hemodynamic instability.

STEMI ECG definition: New ST-segment elevation at the J point in at least 2 contiguous leads of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.15 mV) in women in leads V2 to V3 and/or of ≥1 mm (0.1 mV) in other contiguous precordial leads or limb leads on ECG. New or presumably new left bundle branch block (LBBB) may interfere with ST-elevation analysis and should not be considered diagnostic in isolation.

At non-PCI-capable hospitals, the ACC/AHA recommends thrombolytic therapy administration when the anticipated first medical contact (FMC)-to-device time at a PCI-capable hospital is >120 minutes due to unavoidable delays.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Acute ischemic strokeLevel of Evidence [B, G]

Data from 2 multicenter, open label, alteplase-controlled trials support the use and safety of tenecteplase in the treatment of acute ischemic stroke when administered within 4.5 hours of symptom onset Ref. A meta-analysis found tenecteplase to be noninferior to alteplase for the treatment of acute ischemic stroke Ref.

Based on the American Heart Association (AHA) guidelines for the early management of patients with acute ischemic stroke, it may be reasonable to choose tenecteplase over IV alteplase in patients without IV thrombolysis contraindications who are eligible to undergo mechanical thrombectomy Ref.

Pulmonary embolism, acute (hemodynamically unstable/massive)Level of Evidence [G]

Based on the 2016 American College of Chest Physicians (ACCP) guidelines for antithrombotic therapy for venous thromboembolism disease, thrombolytic therapy is suggested in patients with acute pulmonary embolism who are hemodynamically unstable defined as sustained hypotension (SBP <90 mm Hg for 15 minutes) or with signs/symptoms of shock and without a high bleeding risk.

Pulmonary embolism, acute (hemodynamically stable/submassive)Level of Evidence [G]

Based on the ACCP guidelines for antithrombotic therapy for VTE disease, thrombolytic therapy (eg, tenecteplase) may be considered on an individual basis in select patients with acute pulmonary embolism (PE) without hypotension after systemic anticoagulation has been initiated. In most patients, thrombolytic therapy is not warranted or recommended for acute PE without hypotension (systolic BP >90 mm Hg). However, in patients without hypotension who have severe symptoms or marked cardiopulmonary impairment and show signs of cardiopulmonary deterioration (eg, worsening symptoms, increasing heart rate, decreasing systolic BP, tissue hypoperfusion, worsening gas exchange, increasing cardiac biomarkers, right ventricular dysfunction), the risks vs benefits may be altered in favor of tenecteplase use.

Pulmonary embolism associated with cardiac arrestLevel of Evidence [C, G]

Several case reports suggest that the use of tenecteplase may be beneficial in the treatment of patients in cardiac arrest due to suspected PE Ref. A prospective multicenter observational clinical trial in patients with non-traumatic undifferentiated cardiac arrest failing to respond to advanced cardiac life support measures demonstrated improved rates of return of spontaneous circulation, increased short term survival and neurologically intact survival to hospital discharge when treated with tenecteplase Ref. Subsequently, however, a double-blind, multicenter trial conducted in patients with witnessed out of hospital undifferentiated cardiac arrest (patients with suspected pulmonary embolism were administered open label tenecteplase) did not demonstrate improvement in any outcomes; number of confirmed pulmonary embolism cases were too small to determine benefit in this subpopulation Ref. Additional randomized controlled trials are needed to further define the role of tenecteplase for cardiac arrest due to PE.

Based on the AHA guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, thrombolytics may be considered when PE is presumed or confirmed as the cause of cardiac arrest. Contraindications should be considered but can be overridden since this therapy is potentially lifesaving Ref.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Tissue Plasminogen Activators

Clinical Practice Guidelines

Acute ischemic stroke:

AHA/ASA, “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke,” October 2019

Advanced Cardiac Life Support (ACLS)/Emergency Cardiovascular Care (ECC):

AHA, “2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” October 2015.

AHA, "2010 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” November 2010.

ST-Elevation Myocardial Infarction:

ACC/AHA, “2013 ACC/AHA Guideline for the Management of ST-Elevation Myocardial Infarction,” January 2013

Venous thromboembolism:

“Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report,” February 2016

Administration: IV

Tenecteplase is incompatible with dextrose solutions. Dextrose-containing lines must be flushed with a saline solution before and after administration. Administer as a single IV bolus over 5 seconds. Avoid IM injections and nonessential handling of patient.

PE, acute (off-label use): Administer as an IV bolus over 5 to 10 seconds using a peripheral vein (Kearon 2012; Kearon 2016).

Storage/Stability

Store under refrigeration of 2°C to 8°C (36°F to 46°F) or at room temperature; do not exceed 30°C (86°F). If reconstituted and not used immediately, store in refrigerator and use within 8 hours.

Preparation for Administration: Adult

Tenecteplase should be reconstituted using the supplied 10 mL syringe with TwinPak Dual Cannula Device and 10 mL sterile water for injection. Do not shake when reconstituting. Slight foaming is normal and will dissipate if left standing for several minutes. The reconstituted solution is 5 mg/mL. Any unused solution should be discarded. If reconstituted and not used immediately, store in refrigerator and use within 8 hours.

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat a heart attack.

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums, abnormal vaginal bleeding, bruises without a reason or that get bigger; or any severe or persistent bleeding

• Severe cerebrovascular disease like change in strength on one side is greater than the other, trouble speaking or thinking, change in balance, or vision changes

• Confusion

• Abnormal heartbeat

• Slow heartbeat

• Blue/black/purple skin discoloration

• Change in amount of urine passed

• Severe headache

• Severe dizziness

• Severe dizziness

• Passing out

• Chest pain

• Vision changes

• Muscle pain

• Dark urine

• Severe abdominal pain

• Back pain

• Nausea

• Vomiting

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

High alert medication:

Contraindications

Treatment of STEMI: Active internal bleeding; history of cerebrovascular accident; recent (ie, within 2 months) intracranial/intraspinal surgery or trauma; intracranial neoplasm; arteriovenous malformation or aneurysm; bleeding diathesis; severe uncontrolled hypertension

Additional absolute contraindications (ACC/AHA [O’Gara 2013]): Ischemic stroke within 3 months; prior intracranial hemorrhage; active bleeding (excluding menses); suspected aortic dissection; significant closed head or facial trauma within 3 months

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to tenecteplase or any component of the formulation.

Treatment of PE (off-label): Structural intracranial disease, previous intracranial hemorrhage, ischemic stroke within 3 months, active bleeding, recent brain or spinal surgery, recent head trauma with fracture or brain injury, bleeding diathesis

Warnings/Precautions

Concerns related to adverse effects:

• Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias (eg, sinus bradycardia, accelerated idioventricular rhythm, ventricular premature depolarizations, ventricular tachycardia). Antiarrhythmic therapy should be available during therapy.

• Bleeding: Internal bleeding (intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external bleeding (especially at arterial and venous puncture sites) may occur. Monitor all potential bleeding sites; if serious bleeding occurs, the infusion of tenecteplase and any other concurrent anticoagulants (eg, heparin) and antiplatelets should be stopped and the patient should be treated appropriately.

• Cholesterol embolization: Cholesterol embolization has been reported rarely in patients treated with thrombolytic agents; may present as livedo reticularis, "purple toe" syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, myocardial infarction, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, or rhabdomyolysis and can be fatal.

• Hypersensitivity reactions: Hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, laryngeal edema, rash) have been reported after administration. Monitor closely for hypersensitivity reactions during infusion and for several hours after; initiate appropriate therapy if symptoms of hypersensitivity occur.

• Thromboembolic events: Use may increase risk of thromboembolic events in patients with high probability of left heart thrombus (eg, patients with mitral stenosis or atrial fibrillation).

Disease-related concerns:

• Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy:

• PE: Systolic BP >180 mm Hg or diastolic BP >110 mm Hg; recent bleeding (nonintracranial); recent surgery or invasive procedure; ischemic stroke >3 months previously; anticoagulated (eg, VKA therapy); traumatic CPR; pericarditis or pericardial fluid; diabetic retinopathy; age >75 years; low body weight (<60 kg); female; black (Kearon 2012; Kearon 2016); lumbar puncture within 10 days (ASRA [Horlocker 2012]).

• STEMI: History of chronic, severe, poorly controlled hypertension; significant hypertension on presentation (systolic BP >180 mm Hg or diastolic BP >110 mm Hg); history of prior ischemic stroke >3 months; dementia; traumatic or prolonged CPR (>10 minutes); major surgery (<3 weeks); recent internal bleeding (within 2 to 4 weeks); noncompressible vascular punctures; active peptic ulcer; oral anticoagulant therapy (ACC/AHA [O’Gara 2013]); lumbar puncture within 10 days (ASRA [Horlocker 2012]).

Concurrent drug therapy issues:

• Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. Adjunctive use of parenteral anticoagulants (eg, enoxaparin, heparin, or fondaparinux) is recommended in STEMI patients to improve vessel patency and prevent reocclusion and may also contribute to bleeding; monitor for bleeding (ACC/AHA [O’Gara 2013]).

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in patients with advanced age; increased risk of bleeding. The 30-day mortality in the ASSENT-2 trial of AMI patients was 2.5% for patients <65 years of age, 8.5% for patients 65 to 74 years, and 16.2% for patients ≥75 years. The intracranial hemorrhage rate was 0.4% for patients <65 years, 1.6% for patients 65 to 74 years, and 1.7% for patients ≥75 years. The risks and benefits of use should be weighed carefully in the elderly.

Other warnings/precautions:

• Administration: Avoid intramuscular injections and nonessential handling of the patient for a few hours after administration. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed. Caution with readministration of tenecteplase.

* See Cautions in AHFS Essentials for additional information.

Pregnancy Considerations

The risk of bleeding may be increased in pregnant women. Administer to pregnant women only if the potential benefits justify the risk to the fetus.

Breast-Feeding Considerations

It is not known if tenecteplase is present in breast milk. The manufacturer recommends that caution be exercised when administering tenecteplase to breastfeeding women.

Briggs' Drugs in Pregnancy & Lactation

• Tenecteplase

Adverse Reactions

>10%:

Hematologic & oncologic: Hemorrhage (ASSENT-2 trial: minor: 22%; major: 5%), hematoma (local: minor: 12%; major: 2%)

1% to 10%:

Cardiovascular: Cerebrovascular accident (2%)

Gastrointestinal: Gastrointestinal hemorrhage (minor: 2%; major: 1%)

Genitourinary: Genitourinary tract hemorrhage (minor: 4%; major: <1%)

Hematologic & oncologic: Local hemorrhage (catheter puncture site: minor: 4%; major: <1%)

Respiratory: Pharyngeal bleeding (minor: 3%), epistaxis (minor: 2%)

Frequency not defined:

Cardiovascular: Atrioventricular block, cardiac arrhythmia, cardiac failure, cardiac tamponade, cardiogenic shock, embolism, hypotension, ischemic heart disease (recurrent), mitral valve insufficiency (regurgitation), myocardial reinfarction, myocardial rupture, pericardial effusion, pericarditis, pulmonary edema, thrombosis

Gastrointestinal: Nausea, vomiting

Miscellaneous: Fever

<1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, intracranial hemorrhage, laryngeal edema, respiratory tract hemorrhage, retroperitoneal hemorrhage, skin rash, thrombolytic drug-induced cholesterol embolism (clinical features may include acute renal failure, bowel infarction, cerebral infarction, gangrenous digits, hypertension, livedo reticularis, myocardial infarction, pancreatitis, “purple toe” syndrome, retinal artery occlusion, rhabdomyolysis, spinal cord infarction), urticaria

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Thrombolytic Agent, Fibrin-Specific Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents. Risk C: Monitor therapy

Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants. Risk C: Monitor therapy

Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents. Risk C: Monitor therapy

Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate. Management: Carefully monitor for bleeding. Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details). Risk C: Monitor therapy

Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin. Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation. If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation. Risk D: Consider therapy modification

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur. Management: Avoid coadministration of herbs possessing anticoagulant/antiplatelet properties and thrombolytic agents. If coadministered, monitor for bleeding. Discontinue anticoagulant/antiplatelet herbs 2 weeks prior to surgical, dental or invasive procedures. Risk D: Consider therapy modification

Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased. Risk C: Monitor therapy

Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. Risk C: Monitor therapy

Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. Risk C: Monitor therapy

Test Interactions

Altered results of coagulation and fibrinolytic activity tests

Monitoring Parameters

CBC, aPTT, signs and symptoms of bleeding, ECG monitoring

Advanced Practitioners Physical Assessment/Monitoring

Obtain CBC and aPTT. Patient should be closely monitored for bleeding during and following treatment. Monitor infusion site, neurological status (eg, intracranial hemorrhage), vital signs, and ECG (reperfusion arrhythmias). Arrhythmias may occur; treatment should be immediately available. Bedrest and bleeding precautions should be maintained; avoid IM injections, venipuncture (unless absolutely necessary), and nonessential handling of the patient. If arterial puncture is necessary, an upper extremity vessel that can be manually compressed should be used.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Monitor patient closely for bleeding during and following treatment. Monitor infusion site, neurological status (eg, intracranial hemorrhage), vital signs, and ECG (reperfusion arrhythmias). Arrhythmias may occur; antiarrhythmic drugs should be immediately available. Maintain bedrest and bleeding precautions. Avoid IM injections, venipuncture (unless absolutely necessary), and nonessential handling of the patient. If arterial puncture is necessary, an upper extremity vessel that can be manually compressed should be used. Standard myocardial infarction management should be implemented. Monitor for hypersensitivity reaction during and several hours after infusion. In the event of an upper extremity arterial puncture, manual pressure should be applied for 30 minutes followed by a pressure dressing. Monitor the puncture site closely for evidence of bleeding.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Kit, Intravenous:

TNKase: 50 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Kit, Intravenous:

TNKase: 50 mg

Anatomic Therapeutic Chemical (ATC) Classification

• B01AD11

Generic Available (US)

No

Pricing: US

Kit (TNKase Intravenous)

50 mg (per each): $7,462.63

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Promotes initiation of fibrinolysis by binding to fibrin and converting plasminogen to plasmin. Tenecteplase is essentially alteplase with the exception of 3 point mutations and is more fibrin specific, more resistant to plasminogen activator inhibitor -1 (PAI-1), with a longer duration of action compared to alteplase. Produced by recombinant DNA technology using a mammalian cell line (Chinese hamster ovary cells).

Pharmacodynamics/Kinetics

Distribution: Vd is weight related and approximates plasma volume

Metabolism: Primarily hepatic

Half-life elimination: Biphasic: Initial: 20 to 24 minutes; Terminal: 90 to 130 minutes

Excretion: Clearance: Plasma: 99 to 119 mL/minute

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Bleeding is the most frequent adverse effect of tenecteplase. See Effects on Bleeding.

Effects on Bleeding

Bleeding is the most frequent adverse effect associated with tenecteplase. It is unlikely that ambulatory patients presenting for dental treatment will be taking intravenous anticoagulant therapy.

FDA Approval Date

June 02, 2000

References

Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators, "Primary Versus Tenecteplase-Facilitated Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Acute Myocardial Infarction (ASSENT-4 PCI): Randomised Trial," Lancet, 2006, 367(9510):569-78.

Böttiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008;359(25):2651-2662.[PubMed 19092151]

Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation. 2006;69(3):399-406.[PubMed 16563599]

Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156-2162. doi:10.1161/STROKEAHA.119.025080[PubMed 31318627]

Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Part 2 investigators. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial [published online February, 20 2020]. JAMA. doi:10.1001/jama.2020.1511[PubMed 32078683]

Campbell BCV, Mitchell PJ, Churilov L, et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573-1582. doi:10.1056/NEJMoa1716405.[PubMed 29694815]

Cannon CP, Gibson CM, McCabe CH, et al. “TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. Results of the TIMI 10B Trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators,” Circulation, 1998, 98(25):2805-14.[PubMed 9860780]

De Luca G, Suryapranata H, Stone GW, et al, “Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials,” JAMA, 2005, 293(14):1759-65.[PubMed 15827315]

“Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators,” Lancet, 2001, 358(9282):605-13.[PubMed 11530146]

Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46.[PubMed 26714677]

Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med. 2010;35(1):64-101.[PubMed 20052816]

Jauch EC, Saver JL, Adams HP Jr, et al, “Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,” Stroke, 2013, 44(3):870-947.[PubMed 23370205]

Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in Chest. 2012;142(6):1698-1704]. Chest. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.[PubMed 22315268]

Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.[PubMed 26867832]

Kline JA, Hernandez-Nino J, Jones AE. Tenecteplase to treat pulmonary embolism in the emergency department. J Thromb Thrombolysis. 2007;23(2):101-105. doi: 10.1007/s11239-006-9018-3.[PubMed 17221330]

Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12(4):459-468. doi: 10.1111/jth.12521.[PubMed 24484241]

Keeley EC, Boura JA, and Grines CL, "Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-Elevation Myocardial Infarction: Quantitative Review of Randomised Trials," Lancet, 2006, 367(9510):579-88.[PubMed 16488801]

Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special Circumstances of Resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S501-518.[PubMed 26472998]

Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017;16(10):781-788. doi:10.1016/S1474-4422(17)30253-3.[PubMed 28780236]

Melzer C, Richter C, Rogalla P, et al. Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004;18(1):47-50. doi: 10.1007/s11239-004-0174-z.[PubMed 15744554]

Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402-1141. doi: 10.1056/NEJMoa1302097.[PubMed 24716681]

Nobre C, Thomas B, Santos L, Tavares J. Prolonged chest compressions during cardiopulmonary resuscitation for in-hospital cardiac arrest due to acute pulmonary embolism. Tex Heart Inst J. 2015;42(2):136-138.[PubMed 25873823]

O'Connor RE, Brady W, Brooks SC, et al, “Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):787-817.[PubMed 20956226]

O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481.] Circulation. 2013;127(4):e362-e425.[PubMed 23247304]

Parsons M, Miteff F, Bateman GA, et al, “Acute Ischemic Stroke: Imaging-Guided Tenecteplase Treatment in an Extended Time Window,” Neurology, 2009, 72(10):915-21.[PubMed 19273826]

Parsons M, Spratt N, Bivard A, et al, “A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke,” N Engl J Med, 2012, 366(12):1099-107.[PubMed 22435369]

Perrott J, Henneberry RJ, Zed PJ. Thrombolytics for cardiac arrest: case report and systematic review of controlled trials. Ann Pharmacother. 2010;44(12):2007-2013.[PubMed 21119096]

Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2019;50(12):e440-e441]. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211[PubMed 31662037]

“Single-Bolus Tenecteplase Compared With Front-Loaded Alteplase in Acute Myocardial Infarction: The ASSENT-2 Double-blind Randomised Trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators,” Lancet, 1999, 354(9180):716-22.[PubMed 10475182]

Sinnaeve PR, Alexander JH, Bogaerts K, et al, "Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction," Am Heart J, 2004, 147:993-8.[PubMed 15199346]

TNKase (tenecteplase) [prescribing information]. South San Francisco, CA: Genentech; August 2018.

TNKase (tenecteplase) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; January 2018.

Topol EJ, GUSTO V Investigators, “Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,” Lancet, 2001, 357:1905-14.[PubMed 11425410]

Van de Werf F, Cannon CP, Luyten A, et al, “Safety Assessment of a Single-Bolus Administration of TNK Tissue-Plasminogen Activator in Acute Myocardial Infarction: The ASSENT-1 Trial. The ASSENT-1 Investigators,” Am Heart J, 1999, 137(5):786-91.[PubMed 10220625]

Brand Names: International

Elaxim (IN); Metalize (UA); Metalyse (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CL, CO, CR, CY, CZ, DE, DK, DO, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, KE, KR, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW)

Last Updated 4/28/20